双绒毛膜双胎妊娠中倍他米松清除增强
结果显示单胎与DC双胎的AUC0-∞和CL/F存在显著差异,提示DC双胎可能因两个胎盘单位增强倍他米松代谢,是否需要调整剂量尚需临床研究。
要点
- 单胎与DC双胎的倍他米松AUC0-∞和CL/F存在显著差异。
- DC双胎的倍他米松清除率高于单胎,提示代谢增强。
- 目前尚不明确该药代变化是否需在DC双胎中调整剂量。
核心结论
- 双绒毛膜双胎妊娠可能因两个胎盘单位增强倍他米松经肝CYP3A4和/或胎盘11β-HSD2的代谢。
- 尚需药效学临床研究明确该药代变化对新生儿的临床影响及是否需要调整剂量。
研究设计与样本
- 给予2次肌注倍他米松磷酸钠6 mg加醋酸倍他米松6 mg,首次给药后24小时内采集系列血样。
- 采用经验证的液相色谱-串联质谱法测定倍他米松血浆浓度,并用非房室模型计算药代参数。
主要发现
- 单胎与DC双胎的AUC0-∞几何均值(95%CI)分别为645.1(504.3-825.2)与409.8(311.2-539.6)ng.h/mL,差异显著。
- 单胎与DC双胎的CL/F几何均值(95%CI)分别为17.70(13.84-22.65)与27.87(21.17-36.69),差异显著。
临床怎么用
- 临床药师应关注DC双胎孕妇倍他米松暴露可能低于单胎,但当前证据尚不足以支持常规剂量调整。
- 建议在DC双胎中加强疗效与新生儿结局监测,并推动治疗药物监测相关临床研究。
局限性
- 胎盘转移数据仅为初步结果。
- 缺乏药效学与新生儿结局数据,无法确定药代差异的临床意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: No study has evaluated the betamethasone pharmacokinetics in twin pregnancies according to chorionicity. This study aimed to describe and compare the betamethasone pharmacokinetic parameters in singleton and dichorionic (DC) and monochorionic twin pregnancies in the third trimester of pregnancy. METHODS: Twenty-six pregnant women received 2 intramuscular doses of 6 mg of betamethasone sodium phosphate plus 6 mg betamethasone acetate due to preterm labour. Serial blood samples were collected for 24 hours after the first intramuscular dose of betamethasone esters. Betamethasone plasma concentrations were quantified using a validated liquid chromatography-tandem mass spectrometry analytical method, and the pharmacokinetic parameters were obtained employing a noncompartmental model. Preliminary data on the betamethasone placental transfer are also presented. RESULTS: The geometric mean (95% confidence interval) of AUC0-∞ 645.1 (504.3-825.2) vs. 409.8 (311.2-539.6) ng.h/mL and CL/F 17.70 (13.84-22.65) vs. 27.87 (21.17-36.69) were significantly different, respectively, in singleton pregnancies when compared to DC twins. CONCLUSION: Data from this study suggest that the presence of 2 foetoplacental units may increase the betamethasone metabolism by hepatic CYP3A4 and/or placental 11β-HSD2 enzymes. Pharmacokinetic-pharmacodynamic clinical studies are needed to investigate whether these betamethasone pharmacokinetic changes have clinical repercussions for the newborns and require dose adjustment in DC twin pregnancies.
引用
- Rodrigues GFP, Benzi JRL, Matos LHC, et al. Enhanced elimination of betamethasone in dichorionic twin pregnancies. Br J Clin Pharmacol. 2021. PMID: 34665470. doi:10.1111/bcp.15111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。